NeurAxis (NRXS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of six directors to serve until the next annual meeting or until successors are elected and qualified.
Ratification of Rosenberg Rich Baker Berman, P.A. as independent auditor for the fiscal year ending December 31, 2026.
Approval of an amendment to the 2022 Omnibus Securities and Incentive Plan to increase authorized shares from 1,482,152 to 3,400,000 and extend annual evergreen increases through January 1, 2033.
Approval of the 2025 Employee Stock Purchase Plan.
Board of directors and corporate governance
Six nominees are presented for election to the board: Beth Keyser, Bradley Mitch Watkins, Kristin Ferge, Gilad Aharon, Brian Carrico, and Christopher Robin Brown.
Executive compensation and say-on-pay
Proposal to amend the 2022 Omnibus Securities and Incentive Plan, increasing share authorization and extending the evergreen provision, directly impacts executive and employee compensation incentives.
Introduction of the 2025 Employee Stock Purchase Plan to further align employee interests with shareholders.
Latest events from NeurAxis
- FY2025 revenue rose 33% to $3.6M, with double-digit growth, high margins, and expanded market access.NRXS
Q4 20259 Jul 2026 - Insurance expansion and new product launches set the stage for profitability in early 2025.NRXS
Q2 20248 Jul 2026 - Q3 revenue up 40%, net loss down 80%, with major insurance, FDA, and CPT milestones.NRXS
Q3 20248 Jul 2026 - Category one CPT code, expanded coverage, and strong data position for rapid growth in GI therapies.NRXS
Planet MicroCap Showcase: VEGAS 202530 Jun 2026 - Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets.NRXS
Lytham Partners Spring 2026 Investor Conference28 May 2026 - Neuromodulation therapies for GI disorders drive growth with FDA clearance and strong clinical data.NRXS
Investor presentation28 May 2026 - Q1 2026 revenue up 80% with margin gains, FDA clearances, and ongoing going concern risks.NRXS
Q1 202612 May 2026 - Shareholders will vote on director elections, equity plan amendments, and an employee stock plan.NRXS
Proxy filing29 Apr 2026 - FDA-cleared neuromodulation device targets $22B+ GI market with strong clinical and payer support.NRXS
Corporate presentation19 Apr 2026